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ABSTRACT 22 
Erythrocyte encapsulated thymidine phosphorylase is recombinant Escherichia coli 23 
thymidine phosphorylase encapsulated within human autologous erythrocytes and is under 24 
development as an enzyme replacement therapy for the ultra-rare inherited metabolic 25 
disorder, mitochondrial neurogastrointestinal encephalomyopathy. This study describes the 26 
method validation of a two-step bridging electrochemiluminescence immunoassay for the 27 
detection of anti-thymidine phosphorylase antibodies in human serum according to current 28 
industry practice and regulatory guidelines. The analytical method was assessed for screening 29 
cut-point, specificity, selectivity, precision, prozone effect, drug tolerance and stability. Key 30 
findings were a  correction factor of 129 relative light units for the cut-point determination; a 31 
specificity cut-point of 93% inhibition; confirmed intra-assay and inter-assay precision, assay 32 
sensitivity of 356 ng/mL; no matrix or prozone effects up to 25,900 ng/mL; a drug tolerance 33 
of 156 ng/mL; and stability at room temperature for 24 hours and up to 5 freeze-thaws. 34 
Immunogenicity evaluations of serum from three patients who received erythrocyte 35 
encapsulated thymidine phosphorylase under a compassionate treatment programme showed 36 
specific anti-thymidine phosphorylase antibodies in one patient. To conclude, a sensitive, 37 
specific and selective immunoassay has been validated for the measurement of anti-38 
thymidine phosphorylase antibodies; this will be utilized in a phase II pivotal clinical trial of 39 
erythrocyte encapsulated thymidine phosphorylase.   40 
 41 
 42 
 43 
 44 
 45 
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INTRODUCTION 46 
Enzyme replacement therapies are typically applied to the treatment of individuals with 47 
inherited enzyme deficiency disorders, whereby the deficient enzyme is replaced by regular 48 
infusions of the normal counterpart, with the aim of decelerating the disease progression 49 
process. Current licenced preparations are either purified from natural human or animal 50 
sources, or produced by recombinant technologies, and thus have the potential to induce 51 
undesirable immune responses. Clinical experience has shown that the development of anti-52 
enzyme antibodies is a common occurrence, with many of the approved enzyme replacement 53 
therapies exhibiting immunogenicity rates of 51 - 100%.1,2  Clinical complications of 54 
immunogenic reactions include the modification of therapeutic efficacy and acute infusion 55 
reactions, such as anaphylaxis.  Appropriately, the appraisal of anti-enzyme antibody 56 
formation is a crucial component of the clinical development programme, and is specifically 57 
relevant during the evaluation of the enzyme’s efficacy and safety profile. There is thus a 58 
regulatory expectation that a valid, sensitive, specific and selective immunoassay is 59 
developed for measuring enzyme-specific antibody responses . 3,4 60 
Erythrocyte encapsulated thymidine phosphorylase (EETP) is under development as an 61 
enzyme replacement therapy for the rare metabolic disorder, mitochondrial 62 
neurogastrointestinal encephalomyopathy, abbreviated to MNGIE .5-7 The disease is caused 63 
by mutations in the nuclear TYMP gene encoding for the enzyme thymidine phosphorylase 64 
(TP), leading to elevated concentrations of thymidine and deoxyuridine in cellular and extra-65 
cellular compartments, and ultimately mitochondrial failure due to progressive accumulation 66 
of mitochondrial DNA (mtDNA) defects and mtDNA depletion.8-12  Clinically, MNGIE 67 
manifests as leukoencephalopathy, ptosis and ophthalmoplegia, peripheral polyneuropathy 68 
and enteric neuromyopathy causing severe gastrointestinal dysmotility with cachexia.13 The 69 
disorder invariably leads to death at an average age of 37.6 years. 70 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
4 
 
EETP is produced by encapsulating recombinant Escherichia coli (E.coli) TP within 71 
autologous erythrocytes ex vitro; the loaded cells are then infused into the patient. The 72 
rationale for this approach is based on thymidine and deoxyuridine diffusing across the 73 
erythrocyte membrane via nucleoside transporters into the cell where the encapsulated 74 
enzyme catalyses their metabolism to the normal products. The administration of EETP under 75 
a compassionate treatment programme has shown a sustained reduction or elimination of 76 
plasma thymidine and deoxyuridine concentrations, translating into clinical 77 
improvement.5,6,14,15 EETP therapy has the advantage of prolonging the circulatory half-life 78 
of the enzyme and potentially minimising the immunogenic reactions, which are frequently 79 
observed in enzyme replacement therapies administered by the conventional route. 80 
We describe here the validation of a two-step immunoassay method for the detection of anti-81 
TP antibodies in human serum for supporting a phase II pivotal clinical trial of EETP.  The 82 
analytical method was assessed for screening cut-point, specificity, intra- and inter-assay 83 
precision, sensitivity, selectivity, drug tolerance, prozone effect and stability. 84 
 85 
RESULTS 86 
The key results from this validation study are presented in Table 1. 87 
 88 
Disease state matrix 89 
Of the seven disease matrix samples from untreated patients that were screened, five were 90 
negative for anti-TP antibodies.  The difference in the mean instrument responses between 91 
the patient and normal matrix samples was 10.1%; this was not considered to be significant 92 
(see Supplemental Table 1), indicating that the same cut point can be applied (see below). 93 
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 94 
Screening and specificity cut-point 95 
The signal distribution for the 51 NC samples was normally distributed (p> 0.05) with no 96 
outliers. The validation cut-point was calculated to be 898.5 relative light units (RLU), see 97 
Table 2, first iteration.  98 
Statistically significant differences were evident between the means for analyst, day, plate, 99 
analyst by plate, analyst by day and analyst by day by plate interactions (p<0.001) and also 100 
the variances (p< 0.001)  indicating a dynamic screening cut-point (see online Supplemental 101 
Figure 1).  Each analyst was analysed separately to determine the source of these differences. 102 
For Analyst 1 there were significant differences between the means for day, plate and their 103 
interaction, but not the variances, indicating a floating screening cut-point. For Analyst 2, 104 
there were significant differences between the means for day, plate and their interaction and 105 
the variances, indicating a dynamic cut-point. Due to practical limitations of using a dynamic 106 
cut-point, the validation study continued using Analyst 1, thereby applying a floating cut-107 
point which was calculated as 1066.6 RLU, see Table 2, second iteration. The correction 108 
factor for the screening cut-point for Analyst 1 was estimated to be 128.6 RLU and this was 109 
applied to subsequent assays.  110 
An analysis of the specificity cut-point data revealed a normal distribution and one outlier 111 
which was excluded.  The fixed specificity cut-point was calculated to be 93% inhibition 112 
(Figure 1). Statistically significant differences were evident between the means for analyst, 113 
day, plate, analyst by day, day by plate and analyst by day by plate interactions (p<0.001). 114 
 115 
Sensitivity 116 
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Assay sensitivity analysis was determined from data generated by Analyst 1 only and was 117 
calculated as 356 ng/mL, see Supplemental Table 2.  118 
 119 
Controls 120 
The NC samples were below the cut-point, the LPC samples above the cut-point and the HPC 121 
samples at the high end of the dynamic range for both intra and inter assay analyses, and are 122 
therefore considered suitable. Controls pre-incubated in the presence of 12,500 ng/mL TP 123 
demonstrated RLUs below the cut-point in both intra and inter-assay analyses, with 124 
inhibitions ranging between 80.6 to 98.8%, Table 3.  125 
Assay drift was not observed, as indicated by a mean difference in response readings of the 126 
control samples at the beginning and end of the assay plate being within ± 30%, when 127 
compared to each other (data not shown). 128 
 129 
Drug tolerance 130 
The drug tolerance of the analytical method was determined at 156 ng/mL (Figure 2). 131 
 132 
Selectivity 133 
All low and high spiked samples were above the cut-point without TP and below the cut-134 
point with TP. Inhibitions at the confirmatory drug concentration (12,500 ng/mL) were 135 
observed for the high spiked patient and control samples (Figure 3).  Matrix effects with 136 
regard to the therapeutic enzyme and disease state matrix are therefore not considered 137 
significant. 138 
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 139 
Prozone 140 
The instrument response readings remained above the assay cut-point, therefore prozone 141 
effects were not observed up to a serum anti-TP antibody concentration of 25,900 ng/mL, 142 
2.59-fold higher than the HPC (data not shown). 143 
 144 
Stability 145 
Anti-TP antibodies were stable up to 24 hours at room temperature and for up to five cycles 146 
of freeze-thaw at -70oC (Figure 4). The precision (% CV) of the instrument responses was ≤ 147 
20%. 148 
 149 
Evaluation of serum samples from treated patients  150 
Serum samples from three patients were analysed before treatment and at different time 151 
points during treatment, Table 4. The mean instrument responses for all pre-treatment 152 
samples were below the assay cut-point. For patient 1, one sample after 9 months of 153 
treatment was above the cut-point. For patient 2, all samples during the treatment phase were 154 
above the cut-point. For patient 3, one sample after 5 months of treatment was above the cut-155 
point.  All positive samples from patient 2 were found to be specific in the confirmatory 156 
assay. Positive samples for patients 1 and 3 were confirmed as non-specific antibodies as the 157 
inhibition was below the specificity point of 93%. 158 
 159 
DISCUSSION 160 
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Autologous erythrocyte-mediated enzyme replacement is employed as a strategy for 161 
preventing or minimising the development of immune reactions against therapeutic enzymes. 162 
Our experience includes the treatment of a patient with adenosine deaminase deficiency with 163 
erythrocyte encapsulated adenosine deaminase and the administration of EETP to 5 patients 164 
with MNGIE under a compassionate use programme.5, 6, 14-17   A recombinant E.coli source of 165 
GMP TP has been developed to support a clinical trial of EETP.  Although erythrocyte 166 
encapsulation would be predicted to reduce the immunogenicity of the enzyme, an 167 
intravascular release of TP from damaged erythrocytes is likely to evoke an immunogenic 168 
reaction against a protein of bacterial origin. The evaluation of the immunogenicity of 169 
therapeutic enzymes is an important aspect of clinical development as the formation of anti-170 
enzyme antibodies can negatively influence the efficacy and safety of the proposed treatment.  171 
 172 
In this study, we validated a method for the detection of anti-TP antibodies in the serum of 173 
patients treated with EETP according to published recommendations for the design and 174 
optimisation of immunoassays for the detection of host antibodies against therapeutic 175 
proteins.3, 4, 18-21  To minimise the false positive rate and to increase specificity, a two-step 176 
analysis was adopted;  a screening  assay  for the  identification  of  anti-TP  positive patient  177 
samples, followed by an assay  for  confirming  the  presence  of  anti-TP antibodies. Due to 178 
having the potential to detect all antibody isotypes and classes produced in an immune 179 
response, an electrochemiluminescent bridging immunoassay platform was selected. Fifty-180 
one individual control serum samples were used to determine the 95% confidence interval 181 
used as the cut point factor. The cut-point factor was added to the mean signal for the pooled 182 
NC serum on each plate to establish the cut point. In the second analysis step, a confirmation 183 
assay was developed to confirm the specificity of putatively positive samples identified in the 184 
screening assay. In this approach, PC samples were pre-incubated with and without a high 185 
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concentration of TP to inhibit the assay signal beyond the cut point value; inhibition above 186 
the cut-point confirmed the presence of anti-TP antibodies. Ideally, cut-point assessments 187 
should be conducted using disease state serum samples, however for rare diseases, obtaining 188 
a sufficient number of patient samples is challenging. To address possible differences 189 
between control and diseases matrices, assay selectivity testing was assessed in patient and 190 
NC matrix samples. The bioanalytical guidelines of the EMA and FDA recommend the 191 
testing of at least ten individual sources of sample matrix, however because of the rarity of 192 
MNGIE, only seven patient matrix samples were available for testing.22,23 The mean 193 
instrument responses between the patient and NC matrix samples nevertheless were not  194 
significantly different, therefore demonstrating the absence of disease matrix effects. Testing 195 
a larger number of samples will be contemplated during the clinical trial when more patients 196 
will be available.  197 
 198 
The assay provided an adequate sensitivity of 356 ng/mL of polyclonal antibodies in serum, 199 
this is in the accepted range of 250 – 500 ng/mL in serum for antibody assays in clinical 200 
trials.24 Drug tolerance was 156 ng/mL; in patient compassionate use studies, plasma levels 201 
of free TP are undetectable and therefore assay interference by free TP is considered 202 
negligible. 203 
 204 
No specific anti-TP antibodies were detected in patients 1 and 3, determined using the 205 
confirmatory assay. However, in patient 2 positive anti-TP antibodies were detected after 8 206 
months of treatment (after nine administrations of EETP) onwards. The development of anti-207 
TP antibodies does not necessarily predict the development of  adverse events in patients, but 208 
could potentially impact on the efficacy of TP by inhibiting the pharmacological activity of 209 
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the enzyme through the formation of immune complexes. Another clinical consequence of 210 
anti-body formation is cross-reactivity with an endogenous protein, which performs a key 211 
physiological function.  The development of specific anti-TP antibodies in Patient 2 did not 212 
raise any specific concerns with regard to the efficacy of encapsulated TP, as depletion of the 213 
plasma metabolites improved over the 5.5 years of administration and clinical improvements 214 
were also recorded.15 Nevertheless, heterogeneity in patient antibody responses are often 215 
observed and thus sufficient data should be compiled during clinical development to 216 
characterise antibody response variability.  Guidelines of the FDA and EMA recommend that 217 
specific antibody responses are further analysed for neutralizing capacity.3, 4, 25 Neutralising 218 
antibody assay validation was not included in this study, and although we anticipate that it is 219 
unlikely that neutralising antibodies will be formed due to the encapsulation of TP in the 220 
erythrocyte, a relevant assay will be validated during clinical development and prior to 221 
marketing authorisation applications. Pre-clinical studies with EETP demonstrated specific 222 
anti-TP antibodies in 2/18 treated dogs and 19/60 treated BALB/c mice.7  The development 223 
of specific antibodies against TP is not a surprising observation since senescent erythrocytes 224 
are naturally sequestered from the vascular compartment by macrophages of the monocyte-225 
macrophage system, which is able to present antigens to T lymphocytes.  We have previously 226 
shown that humoral responses can be elicited by the administration of erythrocyte 227 
encapsulated antigens to BALB/c mice.26 One of the advantages of employing the autologous 228 
erythrocyte is that the development of antibodies against the carrier is unlikely, and indeed 229 
this has not been encountered in 25 years of clinical experience.  230 
 231 
To conclude, this assay has appropriate performance characteristics and is considered suitable 232 
for the detection of anti-TP antibodies in human serum.  Further assay refinement will be 233 
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implemented during clinical development to include the validation of a neutralising antibody 234 
assay and detection of IgE antibodies.  235 
 236 
MATERIALS AND METHODS 237 
This validation study was designed to adhere to recommendations for the validation of 238 
immunoassays used for detection of host antibodies against biotechnology products  239 
according to FDA and EMA immunogenicity guidelines and  in compliance with Good 240 
Laboratory Practice (GLP) standards.3, 4, 18-21, 24 241 
Reagents 242 
All reagents were supplied by Meso Scale Discovery, UK unless otherwise stated. The wash 243 
buffer was phosphate-buffered saline (PBS) with 0.05% Tween 20 (Sigma Chemical 244 
Company, UK). Blocker A solution consisted of 5% (w/v) Blocker A in phosphate buffer; the 245 
assay buffer  was 1 volume of 5% Blocker A solution and 4 volumes of wash buffer; and the 246 
Read buffer (4×) was diluted 1 in 2 with ultra-high purity grade water. 247 
Recombinant E. coli (TP, 13 mg/mL) produced by the methodology employed for the 248 
manufacture of clinical GMP material was employed for the development and validation of 249 
this immunoassay (Diatheva, Italy). A 12,500 ng/mL working solution of TP was prepared by 250 
dilution in assay buffer. Biotinylated and sulfo-TAG TP conjugates were prepared as the 251 
capture and detection antigens, respectively, as described previously and were used to 252 
formulate a conjugate mastermix complex working solution containing 300 ng/mL biotin and 253 
300 ng/mL sulfo-TAG in assay buffer.27 254 
 255 
Negative and positive human serum controls 256 
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A negative control (NC) human serum pool was prepared from 15 individual human samples 257 
which had been screened against a positive control calibration curve for the presence of anti-258 
TP antibodies and stored at -20oC until required.  Positive human serum controls (PC) were 259 
prepared from affinity-purified rabbit anti-TP antibody (0.518 mg/mL, custom produced  by 260 
Open Biosystems, Huntsville, USA) diluted with NC sera to produce the low PC just above 261 
the cut-point (LPC, 400 ng/mL) and a high PC giving approximately 75% of the maximum 262 
signal (HPC, 10,000 ng/mL).   Prior to analysis, the NC and PC samples were diluted 1 in 10 263 
with assay buffer. 264 
 265 
Samples from patients with MNGIE 266 
To ascertain that the normal matrix was representative of the disease state matrix, seven 267 
individual treatment-naïve disease state human serum samples were screened and analysed 268 
alongside ten individual NC samples.  269 
Serum samples from three patients with a confirmed diagnosis of MNGIE who had received 270 
2 to 4 weekly infusions of EETP (3.9 to 108 U/Kg body weight) were collected pre-treatment 271 
and at a number of time points after therapy initiation. Samples were stored at -80°C in a 272 
temperature-monitored freezer until sample analysis, by a two-tiered process, a screening 273 
assay to identify samples positive for anti-TP antibodies, followed by a confirmatory assay to 274 
establish if the antibodies were specific to TP.  NC, LPC and HPC samples were included in 275 
each assay run. Approval for the study was obtained from the National Research Ethics 276 
Service Committee. Patient informed consent was obtained prior to the start of treatment.   277 
 278 
Assay procedure 279 
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Assays were performed using an electrochemiluminescent bridging immunoassay. Briefly, 280 
NC, PCs and test samples were diluted in assay buffer with and without TP for 1 hour at 281 
room temperature, after which 75µL were added to wells of a polypropylene 96-well plate 282 
(Fisher Scientific, UK)  followed by 75 µL conjugate mastermix. The plates were covered 283 
and incubated at room temperature for 2 hours with shaking at 800 rpm. Following this, 350 284 
µL Blocker A solution were added to the appropriate wells of a streptavidin gold plate, which 285 
was then covered and incubated at room temperature for 2 hours with shaking at 800 rpm. 286 
The streptavidin plate was then washed three times with 350 µL wash buffer per well using a 287 
plate washer; the last wash was aspirated and the plate blotted dry by inversion over 288 
absorbent paper.  Two 50 µL aliquots from each well of the polypropylene 96-well plate were 289 
transferred to corresponding duplicate wells in the streptavidin plate, which was then covered 290 
and incubated at room temperature for 1 hour, with shaking at 800 rpm.  This was followed 291 
by three washes with 350 µL wash buffer per well using a plate washer; the last wash was 292 
aspirated and the plate blotted dry by inversion over absorbent paper.  Finally 150 µL Read 293 
buffer (2x) were added to each well the plate read on a MSD Sector Imager 6000 within 10 294 
minutes. 295 
 296 
Method validation parameters 297 
Reagent optimisation 298 
Design Expert was used to optimise the concentrations of biotinylated TP and Sulfo-TAG TP.  299 
 300 
PC standard curve for assay sensitivity determination 301 
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PC calibration curves were prepared from working standards (n=2, in duplicate) and 302 
processed using a 4-parameter logistical algorithm; this fitting routine was applied throughout 303 
the determination of screening and specificity cut-point, and assay sensitivity. 304 
 305 
Screening and specificity cut-point 306 
The screening cut-point was assessed to determine the threshold for identifying samples as 307 
negative or potentially positive (equal or above the cut-point) for the presence of anti-TP 308 
antibodies. The methodology applied was that of Shankar et al. 18  where the purpose was to 309 
determine the type of cut-point required (floating, fixed or dynamic), calculate the cut-point 310 
value and determine the specificity (confirmation) cut-point. Fifty-one individual human 311 
serum samples were measured in duplicate, by two analysts, over three plates, on three days.   312 
 313 
The specificity cut-point assay is employed to determine whether samples identified as 314 
potentially reactive in the screening assay are positive or negative for anti-TP antibodies. The 315 
same source of serum samples that were employed in the screening cut-point assay were pre-316 
incubated with TP at a concentration of 12,500 ng/mL, this being ten times the lowest 317 
concentration that was observed to fall below the screening cut-point during assay 318 
development. Each assay run included a PC standard curve, NC, LPC and HPC samples, with 319 
and without TP. 320 
 321 
Assay sensitivity 322 
The sensitivity of the assay is defined by the lowest concentration at which a PC antibody 323 
preparation consistently provides a positive signal in the assay. This was calculated as the 324 
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mean concentration obtained by interpolation of the plate-specific cut-point value against the 325 
PC curve on each of the 18 assay runs described above, and then determining the lowest 326 
concentration that is measured as positive 95% of the time.  Instrument responses, RLUs for 327 
the PC samples were assessed according to their relation to the cut-point. 328 
 329 
PC and NC sample suitability 330 
Intra-assay precision was determined by the replicate analysis of NC (4 independent 331 
preparations of NC,  3 independent preparations of LPC and 3 independent preparations of 332 
the HPC samples in one assay run. An additional set of control samples pre-incubated with 333 
12,500 ng/mL TP was also analysed. Inter-assay precision was determined from the replicate 334 
analysis of 4 independent preparations of NC, 2 independent preparations of LPC and 2 335 
independent preparations of HPC samples, with and without TP on 15 occasions spanning 4 336 
different days, by two analysts. Assay drift was assessed by analysing control samples (+ pre-337 
incubation with TP) in the first and last columns of the assay plate. 338 
 339 
Drug tolerance 340 
The tolerance of the assay to free TP was assessed by pre-incubation of the LPC for one hour 341 
in TP over the final concentration range of 39.1 to 40,000 ng/mL. A sample without TP was 342 
also analysed.  343 
 344 
Selectivity 345 
Assay selectivity was assessed to determine whether the assay was affected by the disease 346 
state matrix or by the potential existence of therapeutic TP in serum samples.  Individual 347 
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control (n=10) and disease (n=7) serum samples were unspiked and spiked with anti-TP 348 
antibodies at low (400 ng/mL) and high (10,000 ng/mL) concentrations. Two aliquots of 349 
sample were prepared and incubated for 1 hour, one aliquot with buffer and the other aliquot 350 
with assay buffer containing free TP (12,500 ng/mL). The samples were distributed over four 351 
assay runs. The percentage inhibition of signal in the presence of free TP was calculated 352 
using the formula described in Data handling and statistics. 353 
 354 
Prozone 355 
Assay prozone caused by high anti-TP antibody levels was investigated by serial dilution of a 356 
high spiked sample (containing anti-TP antibodies at a concentration of 25,900 ng/mL) with 357 
assay buffer.  358 
 359 
Stability 360 
The effect of anticipated sample handling conditions on assay performance were evaluated, 361 
specifically bench top storage at room temperature (nominally 22oC) and repeated freeze-362 
thaw cycles.  Room temperature effects were assessed by thawing one set of PC samples for 363 
approximately 24 hours (expected maximum duration that samples would be left thawed) and 364 
an addition set for baseline assessment,  just prior to analysis (n=3, in duplicate). The effect 365 
of repeated freeze-thaw cycles on the stability of anti-TP antibodies was assessed by 366 
subjecting PC samples to three and five freeze-thaw cycles,  with each cycle consisting of a 367 
minimum of two hours at room temperature, followed by storage at -70oC for at least 12 368 
hours (n = 3, in duplicate). An additional set of PC samples for baseline assessment was 369 
thawed prior to analysis. Stability was verified if the mean precision (% CV) and mean 370 
percent difference from the baseline responses were ≤20%. 371 
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 372 
Data handling and statistics 373 
Instrument responses are reported as mean values of RLU. All data acquisition, processing 374 
and evaluations were performed using the Watson Laboratory Information Management 375 
System version 7.2, Microsoft Excel and Meso Scale Discovery Workbench version 3.0.185. 376 
Data for cut-point calculation was analysed using SAS Version 9.1.3. 377 
 378 
Assay cut-point evaluation was performed using the statistical methodology described by 379 
Shankar et al.18 Measurements for each of the 51 human serum samples (n=18, in duplicate) 380 
were averaged and tested for normality using the Shapiro Wilk’s test28; logarithmic  (base 10) 381 
or square root transformation was applied to non-normally distributed data. An assessment 382 
for outliers was made using the Studentized Deleted Residuals whereby residues <-3 or >3 383 
standard deviations (SD) were excluded. Once outliers were removed, data was reassessed for 384 
normality; the validation cut-point was defined as the 95% Quantile for non-normally 385 
distributed data, or the mean + 1.645*SD for normally distributed data.  386 
 387 
To assess the type of screening cut-point to apply, an analysis of variance method was 388 
applied to assess for any analyst, plate and day differences on either the untransformed or 389 
transformed data, depending on the outcome of the Shapiro Wilk’s test above. Analyst, plate, 390 
day and their interactions were set as fixed factors, whereas subject was included as a random 391 
effect.  Levene’s test for homogeneity of variance was performed.29 A fixed screening cut-392 
point was indicated if there were no differences or variances, whereas a floating cut-point 393 
was reported if there were differences between means only, otherwise a dynamic screening 394 
cut-point was required.18 The Correction Factor was calculated as the validation cut-point 395 
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minus the mean of the NC values from the validation runs.  The screening cut-point was 396 
defined as either the validation cut-point or the mean of NC values from the in study run + 397 
Correction Factor, depending on whether the means and variances between runs were similar. 398 
 399 
The fixed specificity cut-point was calculated using the method of Shankar et al. 18 For each 400 
sample the percentage inhibition of signal in the presence of free TP was calculated as 401 
follows: 402 
	ℎ	
	% = 		100 × 1 − 	ℎ	
	ℎ	
	  
Data was assessed for outliers and normal distribution and treated accordingly, as described 403 
above. For normally distributed data, the fixed specificity cut-point was calculated as mean % 404 
inhibition + 3.09 x SD. For data not normalised by transformations, the specificity cut-point 405 
was calculated as medium + 99% quantile. Analysis of variance techniques were applied to 406 
assess for analyst, plate and day differences. 407 
 408 
In the event of differences between analysts for either inhibited or uninhibited samples, the 409 
sensitivity analysis was performed separately for each analyst.  Each dilution curve was 410 
analysed using a four-parameter model. For a floating cut-point, separate curves were 411 
analysed for each plate, whereas for a fixed cut-point the data were combined from all plates.  412 
The screening assay cut-point determined to be appropriate for the method was back-413 
calculated onto the standard curve for each plate to obtain the log concentrations of the 414 
screening cut-points. These were averaged across all plates and a 95% confidence interval 415 
obtained for the overall mean on the log scale. The back transformed upper 95% confidence 416 
interval was calculated, which was defined as the sensitivity of the assay. 417 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
19 
 
 418 
ACKNOWLEDGEMENT 419 
This work was supported by a Medical Research Council grant (reference MR/K025406/1). 420 
We highly appreciate the contributions of Dr Moshe Baru, Orphan Technologies. 421 
 422 
AUTHOR CONTRIBUTIONS 423 
M.L, D.P, CG, J.H., M.S. and B.B. contributed to the design and implementation of the 424 
research, to the analysis of the results and to the writing of the manuscript. 425 
 426 
References 427 
1. Baldo, B.A. (2015). Enzymes approved for human therapy: indications, mechanisms and 428 
adverse effects. BioDrugs. 29, 31-55. 429 
2. Kishnani, P.S., Dickson, P.I., Muldowney, L., Lee, J.J., Rosenberg, A., Abichandani, R., et 430 
al. (2016). Immune response to enzyme replacement therapies in lysosomal storage diseases 431 
and the role of immune tolerance induction. Mol. Genet. Metab. 117, 66-83.  432 
3. FDA. Guidance for Industry. Immunogenicity Assessment for Therapeutic Protein 433 
Products. (2014). p. 1–39. Available from: 434 
https://www.fda.gov/downloads/drugs/guidances/ucm338856.pdf. 435 
4. European Medicines Agency. Guideline on Immunogenicity Assessment of therapeutic 436 
Proteins. (2017). p. 1–24. Doc Ref. EMEA/CHMP/BMWP/14327/2006 Rev 1. 437 
5. Godfrin, Y., Horand, F.,  Franco, R., Dufour, E.,  Kosenko, E.,  Bax, B.E. et al. (2012). 438 
Meeting highlights: international seminar on the red blood cells as vehicles for drugs. Expert. 439 
Opin. Biol. Ther. 12, 127- 133. 440 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
20 
 
6. Godfrin, Y.,  Bax, B.E. (2012). Enzyme bioreactors as drugs. Drugs. Fut. 37, 263-272. 441 
7. Levene, M., Coleman, D., Kilpatrick, H., Fairbanks, L., Gangadharan, B., Gasson, C. et al.  442 
(2013). Preclinical toxicity evaluation of erythrocyte-encapsulated thymidine phosphorylase 443 
in BALB/c mice and Beagle dogs: an enzyme replacement therapy for mitochondrial 444 
neurogastrointestinal encephalomyopathy. Toxicol. Sci. 131, 311-324. 445 
8. Hirano, M., Silvestri, G., Blake, D.M., Lombes, A., Minetti, C., Bonilla, E. et al. (1994). 446 
Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE): clinical, biochemical, 447 
and genetic features of an autosomal recessive mitochondrial disorder. Neurology. 44, 721-448 
727. 449 
9. Nishino, I., Spinazzola, A., Hirano, M. (1999). Thymidine phosphorylase gene mutations 450 
in MNGIE, a human mitochondrial disorder. Science. 283, 689-692. 451 
10. Marti, R., Nishigaki, Y.,  Hirano, M. (2003). Elevated plasma deoxyuridine in patients 452 
with thymidine phosphorylase deficiency. Biochem. Biophys. Res. Commun. 303,14-18. 453 
11. Nishigaki, Y., Marti, R., Copeland, W.C., Hirano, M. (2003). Site-specific somatic 454 
mitochondrial DNA point mutations in patients with thymidine phosphorylase deficiency. J 455 
Clin. Invest. 111, 1913-1921. 456 
12. Valentino, M.,  Martí, R., Tadesse, S., López, L., Manes, J., Lyzak, J. et al. (2007). 457 
Thymidine and deoxyuridine accumulate in tissues of patients with mitochondrial 458 
neurogastrointestinal encephalomyopathy (MNGIE).  FEBS. Lett. 581, 3410-3414. 459 
13. Garone, C., Tadesse, S., Hirano, M. (2011). Clinical and genetic spectrum of 460 
mitochondrial neurogastrointestinal encephalomyopathy. Brain. 134, 3326-3332. 461 
14. Moran, N.F., Bain, M.D., Muqit, M., Bax, B.E. (2008). Carrier erythrocyte entrapped 462 
thymidine phosphorylase therapy in MNGIE. Neurology. 7, 686-688. 463 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
21 
 
15. Bax, B.E., Bain, M.D., Scarpelli, M., Filosto, M., Tonin, P., Moran, N.F. (2013). Clinical 464 
and biochemical improvements in a patient with MNGIE following enzyme replacement. 465 
Neurology. 8, 1269-1271. 466 
16. Bax, B.E., Bain, M.D., Fairbanks, L.D., Webster, A.D.B., Chalmers, R.A. (2000). In vitro 467 
and in vivo studies of human carrier erythrocytes loaded with polyethylene glycol-conjugated 468 
and native adenosine deaminase. Br. J. Haematol. 109, 549-554. 469 
17. Bax, B.E., Bain, M.D., Fairbanks, L.D., Webster, A.D.B., Ind, P.W., Hershfield,  M.S., 470 
Chalmers, R.A. (2007). A nine year evaluation of carrier erythrocyte encapsulated adenosine 471 
deaminase therapy in a patient with adult-type adenosine deaminase deficiency. Eur. J. 472 
Haematol. 79, 338-348. 473 
18. Shankar, G., Devanarayan, V., Amaravadi L, Barrett YC, Bowsher R, Finco-Kent D. et 474 
al. (2008). Recommendations for the validation of immunoassays used for detection of host 475 
antibodies against biotechnology products. J. Pharm. Biomed. Anal. 48, 1267-1281.  476 
19. The UK Good Laboratory Practice Regulations (Statutory Instrument 1999 No. 3106, as 477 
amended by Statutory Instrument 2004 No. 994). 478 
20. OECD Principles of Good Laboratory Practice (as revised in 1997), ENV/MC/CHEM 479 
(98)17. 480 
21. EC Commission Directive 2004/10/EC of 11 February 2004 (Official Journal No. L 481 
50/44). 482 
22. FDA. Guidance for Industry. Bioanalytical Method Validation. (2018). p. 1–41. Available 483 
from: https://www.fda.gov/downloads/drugs/guidances/ucm070107.Pdf 484 
23. European Medicines Agency. Guideline on bioanalytical method validation (2011). p. 1-485 
23. Doc Ref. EMEA/CHMP/EWP/192217/2009 Rev. 1 Corr. 486 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
22 
 
24. Mire-Sluis, A.R.,  Barrett, Y.C., Devanarayan, V.,  Koren, E., Liu, H., Maia, M. et al. 487 
(2004). Recommendations for the design and optimization of immunoassays used in the 488 
detection of host antibodies against biotechnology products. J. Immunol. Methods. 289, 1-16. 489 
25. Gupta, S., Devanarayan, V., Finco, D., Gunn, G.R., Kirshner, S., Richards, S., Rup, B., 490 
Song, A., Subramanyam, M. (2011). Recommendations for the validation of cell-based 491 
assays used for the detection of neutralizing antibody immune responses elicited against 492 
biological therapeutics.  J. Pharm. Biomed. Anal. 55, 878-888. 493 
26. Murray, A.M., Pearson, I.S., Chalmers, R.A., Bain, M.D., Bax, B.E. (2006).  The mouse 494 
immune response to carrier erythrocyte entrapped antigens.  Vaccine. 24, 6129-6139. 495 
27. Gasson, C., Levene, M., Bax, B.E. (2013).  The development and validation of an 496 
immunoassay for the measurement of anti- thymidine phosphorylase antibodies in mouse and 497 
dog sera. J. Pharm. Biomed. Anal. 72, 16-24. 498 
28. Shapiro, S.S., Wilk, M.B. (1965).  An analysis of variance test for normality (complete 499 
samples). Biometrika. 52, 591-611. 500 
29. Levene, H. (1960). Robust tests for equality of variances. In: Contributions to Probability 501 
and Statistics. OLKIN et al, Eds.  (California, Stanford University Press).  pp 278-292. 502 
 503 
 504 
 505 
 506 
 507 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
23 
 
Figure 1. Specificity cut-point. To establish the specificity cut-point, 51 individual control 508 
serum samples were pre-incubated with TP at a concentration of 12,500 ng/mL, and analysed 509 
in duplicate by two analysts over three plates on three days to assess % signal inhibition. 510 
Significant differences were observed between the means for analyst, day, plate, analyst by 511 
day, day*plate and analyst*day*plate interactions (p< 0.001).  Data is expressed as mean % 512 
signal inhibition ± SD. 513 
 514 
Figure 2. Assay tolerance to free TP. Instrument response as function of TP concentration. 515 
The LPC was spiked with TP over a concentration range of 39.1 to 40,000 ng/mL and 516 
incubated for 1 hour before analysis. The blue arrow indicates the assay drug tolerance. 517 
 518 
Figure 3. Assay selectivity.  Individual control (n=10) and disease (n=7) serum samples, 519 
were unspiked or spiked with anti-TP antibodies at low (400 ng/mL) and high (10,000 520 
ng/mL) concentrations. Two aliquots of each sample were prepared and incubated for 1 hour, 521 
one aliquot with buffer and the other aliquot with free TP (12,500 ng/mL). Dotted line 522 
represents assay cut-point. Data is expressed as log mean RLU ± SD. 523 
 524 
Figure 4. Stability of anti-TP antibody after 24 hours at room temperature and after 525 
repeated freeze-thaw cycles.  The dashed lines represent the assay cut-point range. Data is 526 
expressed as log mean RLU ± SD. 527 
 528 
 529 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
24 
 
Table 1. Summary of key validation parameters for the assessment of anti-TP 530 
antibodies in human serum. 531 
Validation Parameter Results 
Positive control standard range 2.44 ng/mL to 10,000 ng/mL 
Correction factor for cut-point calculation 129 RLUa 
Screening cut-point Floating cut-point 
Specificity cut-point 93.0% 
Assay sensitivity  356 ng/mL 
  
Intra-assay performance Precision, CV (%) 
Negative control  14.5 
Low positive control  11.1 
High positive control  1.0 
  
Inter-assay performance Mean precision, CV (%) 
Negative control 43.3 
Low positive control 40.6 
High positive control 30.5 
Assay drift Not present 
  
Minimum required dilution (MRD) 1 in 10 
Selectivity (matrix effects) Not present 
Prozone Not present up to 25,900 ng/mL 
Drug tolerance Tolerant up to 156 ng/mL 
Confirmatory drug concentration 12,500 ng/mL 
  
Stability  
Room temperature Up to 24 hours 
Freeze-thaw Up to five freeze-thaw cycles 
 532 
a
 RLU; relative light unit 533 
 534 
 535 
 536 
 537 
 538 
 539 
 540 
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Table 2. Screening cut-point determination. The cut point was determined using 51 541 
individual lots of serum, analysed in duplicate, by two analysts, over 3 plates, on 3 days.  The 542 
cut-point was calculated as the RLU + 1.645*SD. The first iteration represents data analysed 543 
from Analysts 1 and 2. Data from Analyst 2 were removed for the second iteration. 544 
Parameter RLUa 
 First iteration Second Iteration 
Mean 797.9 914.3 
n 36 18 
SD 61.2 92.6 
Cut point 898.5 1066.6 
Mean of negative controls 814.2 938.0 
Correction factor  128.6 
a
 RLU; relative light unit 545 
 546 
 547 
 548 
 549 
 550 
 551 
 552 
 553 
 554 
 555 
 556 
 557 
 558 
 559 
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Table 3. Intra and inter-assay analysis of control samples with and without pre-560 
incubation with TP. 561 
 Intra assay Inter-assay 
Control 
sample 
RLUa 
Mean ± SD 
CV (%) % inhibition RLU 
Mean ± SD 
CV (%) % inhibition 
NC 865 ± 126 14.5  483 ± 209 43.3  
NC+TPb ND ND ND 87 ± 10 11.0 80.6 
LPC 1505 ± 167 11.1  919 ± 373 40.6  
LPC +TP 151 ± 8 5.3 90.0 103 ± 27 25.8 88.9 
HPC 18111 ± 181 1.0  12680 ± 3873 30.5  
HPC + TP 265 ± 3 1.0 98.5 158 ± 59 37.4 98.8 
       
aRLU; relative light unit 562 
bTP; thymidine phosphorylase 563 
 564 
 565 
 566 
 567 
 568 
 569 
 570 
 571 
 572 
 573 
 574 
 575 
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Table 4.  Screening analysis and confirmatory assay of positive patient samples 577 
Patient ID Treatment 
(months) 
Screening 
Assay  
(-TPa) 
Confirmatory assay 
% inhibition Specificity 
1 Pre-treatment Negative   
 9 Positive 73.7 Non-specific 
 15 Negative   
 21 Negative   
 28 Negative   
2 Pre-treatment Negative   
 8 Positive 95.5 Specific 
 16 Positive 98.8 Specific 
 22 Positive 97.3 Specific 
 28 Positive 98.1 Specific 
 35 Positive 98.5 Specific 
 41 Positive 98.8 Specific 
 49 Positive 99.1 Specific 
 60 Positive 99.0 Specific 
 73 Positive 97.6 Specific 
3 Pre-treatment Negative   
 6 Positive 75.6 Non-specific 
 578 
aTP; thymidine phosphorylase 579 
 580 
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 582 
 583 
 584 
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 586 
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Supplemental Figure 1. Screening cut-point. To establish the screening cut-point, 51 individual 
control serum samples were analysed in duplicate by two analysts over three plates on three days. 
Significant differences were observed between means for analyst, day, plate, analyst*plate, 
analyst*day and analyst*day*plate interactions (p< 0.001) and variances (p<0.001). Data is expressed 
as mean RLU ± SD.  
 
 
 
 
 
 
 
 
 
 
 
Supplemental Table 1. Comparison of instrument responses to negative control and disease 
state matrices. 
Serum sample Instrument response (RLU
a) 
Mean ± SD CV (%) 
Disease (n=5) 1169 ± 388 33.2 
Healthy control (n=10) 1301 ± 141 10.9 
a RLU; relative light unit 
 
Supplemental Table 2. Sensitivity analysis for Analyst 1 for each of 9 plates. 
 
 
 
 
 
 
 
 
 
a RLU; relative light unit  
bScreening cut point = Negative control mean + Correction Factor (128.6) 
c Upper log mean sensitivity =Mean + (SD/√n)*t 
 
Plate Mean RLUa 
Negative 
control 
Screening cut 
pointb (RLU) 
Log sensitivity 
level 
1 1037.0 1165.6 1.171 
2 981.0 1109.6 2.233 
3 905.0 1033.6 2.422 
4 920.5 1049.1 3.114 
5 818.0 946.6 2.472 
6 810.5 939.1 2.243 
7 987.5 1116.1 1.803 
8 1107.0 1235.6 2.119 
9 875.5 1004.1 2.431 
Log mean sensitivity level + SD 2.223 ± 0.528 
Log mean sensitivity Upper 95% CIc 2.551 
Mean sensitivity Upper 95% CI 355.53 
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